Evaluation of Drug-Drug Interactions Between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine.

CONCLUSIONS: No dose adjustment is required during coadministration of raltegravir, tenofovir DF, or emtricitabine with the 3D regimen. Rilpivirine is not recommended and efavirenz is contraindicated for coadministration with the 3D regimen. PMID: 26953200 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/26953200?dopt=Abstract

Source: Antimicrobial Agents and Chemotherapy - March 7, 2016 Category: Microbiology Authors: Khatri A, Dutta S, Dunbar M, Podsadecki T, Trinh R, Awni W, Menon R Tags: Antimicrob Agents Chemother Source Type: research